A Phase 2 interventional study of Blinatumomab and background treatment in Primary Sjögren's Syndrome (pSS), sponsored by Beijing Tongren Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Beijing Tongren Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.
Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 80th largest by planned enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 25 of the 29 other live ones, and was the 105th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:
Ocumension Therapeutics (Suzhou) Co., Ltd · Sites in China
Ages 30–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
Jin Yang · Sites in China
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 11 · Phase 4 9
First in 2010; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 83 interventional studies, 100 across the 23 observational. Of the 50 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 106 have an industry lead sponsor. The 10 most frequent:
Beijing Tongren Hospital is the lead sponsor of 165 studies on the registry; 54 are open to participants now.
Beijing Tongren Hospital has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
8 of the studies in Dry Eye Syndromes with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06360133Phase 3VivaVision Biotech, IncStudy of 5% VVN001 Ophthalmic Solution in Dry Eye Disease | 2027-04-30 |
| NCT07940452Eye & ENT Hospital of Fudan UniversityA Novel Eye Wash Solution for DED Treatment | 2026-11 |
| NCT07623382The First Affiliated Hospital of Xiamen UniversityHuman Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease | 2026-11-30 |
| NCT05605314Peking University Third HospitalClinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye | 2027-01-01 |
| NCT07679685Beijing Tongren HospitalPerfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Dry Eye Syndromes with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab. The main questions it aims to answer are:
Is low-dose blinatumomab more effective in patients with moderate-to-severe primary Sjögren's Syndrome who have an inadequate response or intolerance to conventional treatment? How does blinatumomab affect B cells, antibody levels, and the immune system in these participants?
Researchers will compare background treatment plus low-dose Blinatumomab with background treatment only to see if low-dose Blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome.
Participants will:
Receive background treatment for 24 weeks, including hydroxychloroquine 400 mg each day, methylprednisolone 8 mg each day, and sodium hyaluronate eye drops 4 times each day.
If assigned to the blinatumomab group, receive blinatumomab by continuous intravenous infusion for 5 days during week 1 and again for 5 days during week 3. The dose will be 9 micrograms per day.
Attend regular follow-up visits for clinical assessments, laboratory tests, and monitoring of treatment effectiveness and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory values meeting all of the following requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive background treatment alone for 24 weeks and will not receive blinatumomab. The background treatment includes: (1) hydroxychloroquine, 400 mg/day; (2) methylprednisolone, 8 mg/day; and (3) sodium hyaluronate eye drops, 4 times/day.
Drug: background treatment
In addition to the same background treatment as the control group, participants will receive low-dose, short-course blinatumomab treatment in the Department of Rheumatology and Immunology. The dosing regimen is as follows: 1. First cycle: blinatumomab 9 μg/day by continuous intravenous infusion for 5 consecutive days, for a total dose of 45 μg. 2. Second cycle: the same dose and administration schedule will be repeated 1 week later.
Drug: Blinatumomab · Drug: background treatment
Participants will receive low-dose, short-course blinatumomab treatment. The dosing regimen is as follows: 1. First cycle: blinatumomab 9 μg/day by continuous intravenous infusion for 5 consecutive days, for a total dose of 45 μg. 2. Second cycle: the same dose and administration schedule will be repeated 1 week later.
All the participants will receive background treatment for 24 weeks. The background treatment includes: (1) hydroxychloroquine, 400 mg/day; (2) methylprednisolone, 8 mg/day; and (3) sodium hyaluronate eye drops, 4 times/day.
NEI corneal fluorescein staining score
Corneal epithelial damage will be assessed using the National Eye Institute (NEI) corneal fluorescein staining scale. Each cornea is divided into five regions, and each region is scored from 0 to 3. The total score ranges from 0 to 15, with higher scores indicating more severe corneal epithelial damage. The outcome is calculated as the Week 24 total score minus the baseline score. A decrease of 3 points or more from baseline is defined as a response.
Time frame: Baseline and Week 24
ESSDAI score
Systemic disease activity will be assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). The ESSDAI evaluates disease activity across 12 organ or system domains and has a total score ranging from 0 to 123, with higher scores indicating greater disease activity. The outcome is calculated as the Week 24 total score minus the baseline score. A decrease of 3 points or more from baseline is defined as a response.
Time frame: Baseline and Week 24
NEI score at follow-up visits
Corneal epithelial damage will be assessed using the National Eye Institute corneal fluorescein staining scale. The total score ranges from 0 to 15, with higher scores indicating more severe corneal epithelial damage. Changes from baseline will be assessed at each prespecified follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 20
OSDI score
Dry eye symptoms and their effects on visual function and quality of life will be assessed using the 12-item Ocular Surface Disease Index (OSDI). The total score ranges from 0 to 100, with higher scores indicating more severe symptoms and greater impairment. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
FBUT
Tear film stability will be assessed using fluorescein tear film break-up time (FBUT). FBUT is measured in seconds from eye opening until the first break in the fluorescein-stained tear film is observed. Measurements will be repeated for each eye and averaged according to the study protocol. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Schirmer I test
Tear secretion will be assessed using the Schirmer I test without topical anesthesia. A standard filter paper strip is placed in the lower conjunctival sac, and the length of wetting is measured in millimeters after 5 minutes. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
NIBUT
Tear film stability will be assessed using non-invasive tear film break-up time (NIBUT) measured with an ocular surface analyzer. The instrument records the time from completion of a blink to the first detected tear film break. Measurements are generally repeated three times and averaged. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Tear meniscus height
Tear secretion and distribution will be assessed by measuring lower tear meniscus height using an ocular surface analyzer. The upper and lower boundaries of the lower tear meniscus beneath the central pupil are identified, and tear meniscus height is calculated in millimeters. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Tear film lipid layer thickness
Tear film lipid layer thickness will be measured using an ocular surface analyzer to assess meibomian gland-related tear film function. Lipid layer thickness is quantified using interference color units, with 1 interference color unit corresponding to approximately 1 nm. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Incomplete blink rate
Blinking behavior will be assessed using an ocular surface analyzer. The incomplete blink rate is calculated as the number of incomplete blinks divided by the total number of blinks during the observation period and expressed as a percentage. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
ESSDAI at follow-up visits
Systemic disease activity will be assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), which evaluates 12 organ or system domains. Higher scores indicate greater disease activity. Changes from baseline will be assessed at prespecified follow-up visits.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 20
ESSPRI
Patient-reported symptoms will be assessed using the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). The ESSPRI evaluates dryness, fatigue, and pain on 0-to-10 numeric rating scales. The total score is the average of the three domain scores, with higher scores indicating more severe symptoms. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
MFI-20
Fatigue will be assessed using the 20-item Multidimensional Fatigue Inventory (MFI-20), which includes general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The total score ranges from 20 to 100, with higher scores indicating greater fatigue. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Unstimulated salivary flow rate
Salivary gland function will be assessed by measuring unstimulated whole salivary flow. Participants will collect saliva at rest for 15 minutes, and the salivary flow rate will be calculated in milliliters per minute. Changes from baseline will be assessed at each follow-up visit.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24
Autoantibody titers
Serum autoantibodies, including anti-SSA/Ro, anti-SSB/La, anti-dsDNA, anti-Sm, anti-RNP, antinuclear antibodies (ANA), and antineutrophil cytoplasmic antibodies (ANCA), will be measured. Changes in antibody titers from baseline will be assessed. The proportion of participants whose antibody status changes from positive to negative will also be evaluated.
Time frame: Baseline and Weeks 4, 12, and 24
Immunoglobulin levels
Serum immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) concentrations will be measured to assess changes in humoral immune status. Changes from baseline will be evaluated, with particular attention to changes in IgG levels.
Time frame: Baseline and Weeks 2, 4, 12, and 24
Peripheral blood lymphocyte subsets
Peripheral blood lymphocyte subsets will be assessed by flow cytometry. Absolute counts of lymphocyte subsets and detailed B-cell subsets will be measured to evaluate the effects of treatment on B cells and T cells.
Time frame: Baseline and Weeks 2, 4, 12, and 24
BCR/TCR repertoire
B-cell receptor (BCR) and T-cell receptor (TCR) repertoires will be assessed by high-throughput sequencing of lymphocytes isolated from peripheral blood. Changes in immune repertoire characteristics at follow-up visits will be compared with baseline as an exploratory assessment of treatment effects on adaptive immunity.
Time frame: Baseline and Weeks 4, 12, and 24
Adverse events
Safety will be assessed by recording adverse events (AEs), serious adverse events (SAEs), adverse events leading to treatment discontinuation, clinically significant laboratory abnormalities, electrocardiogram abnormalities, and changes in vital signs. Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: From baseline through Week 24
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Oct 2027, 12 months later.
Of 91 phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 12. This study's planned 12 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab